title: Determinants, outcomes and costs of ceftriaxone v. amoxicillin-clavulanate in the treatment of community-acquired pneumonia at Witbank Hospital.
abstract: BACKGROUND
  Community-acquired pneumonia (CAP) is a major cause of death and morbidity worldwide. Treatment is centred on antibiotics with ceftriaxone and amoxicillin-clavulanate being some of the most commonly prescribed agents.
  
  
  OBJECTIVE
  To compare treatment outcomes and costs in patients receiving either of these two antibiotics at Witbank Hospital (WH).
  
  
  METHODS
  A total of 200 randomly selected adult patient files (100 receiving ceftriaxone and 100 amoxicillin-clavulanate) recording a diagnosis of CAP were studied to determine the length of hospital stay, comorbid conditions and treatment outcomes. A descriptive and comparable analysis was performed.
  
  
  RESULTS
  Male gender, higher CURB-65 scores and death were associated with the use of ceftriaxone. Severity of disease and previous antibiotic exposure influenced the duration of hospital admission.
  
  
  CONCLUSIONS
  Gender and severity of disease (based on the CURB-65 score) were the determinants of antibiotic choice at WH. Male gender increased the likelihood of being treated with ceftriaxone, as did a CURB-65 score of > 2. There were no differences in the outcomes of CAP patients treated with ceftriaxone compared with those treated with amoxicillin-clavulanate. Irrespective of antibiotic used, gender and severity of disease influenced treatment outcomes. Male gender was associated with a higher mortality and longer hospital stay. The average duration of stay for both antibiotics was not significantly different. Thus, only level 1 and 2 costs need to be considered when comparing the two regimens. On this basis, ceftriaxone was cheaper than amoxicillin-clavulanate.
authors.forename: S N
authors.initials: SN
authors.lastname: Xaba
authors.forename: O
authors.initials: O
authors.lastname: Greeff
authors.forename: P
authors.initials: P
authors.lastname: Becker
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000631:Aminopyridines / Q000008:administration & dosage* / Q000191:economics; D002443:Ceftriaxone / Q000191:economics / Q000627:therapeutic use*; D019818:Clavulanic Acid / Q000008:administration & dosage* / Q000191:economics; D017714:Community-Acquired Infections / Q000188:drug therapy*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000150:complications / Q000188:drug therapy*; D012737:Sex Factors; D016896:Treatment Outcome
chemical_list: D000631:Aminopyridines; D004338:Drug Combinations; D019818:Clavulanic Acid; D002443:Ceftriaxone; C045742:amlexanox